CERO THERAPEUTICS HOLDINGS, INC.

SOUTH SAN FRANCISCO, CA · Founded 2021 · CIK 0001870404 · Biotech · Public

Engineered T cell therapies with multi-modal tumor clearance mechanisms

cero.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$16M
3 Form D · May 2025
17 months since last filing
Contracts
—
No federal contracts on record
Patents
10
2 granted · 8 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$10,193,654
Private capital raisedForm D · SEC$1,250,000
Private capital raisedForm D · SEC$5,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2315Bond Biosciences, Inc.—$18M
2316Moleculin Biotech, Inc.—$6.0M
2317ProtoKinetix, Inc.—$3.8M
2318CERO THERAPEUTICS HOLDINGS, INC.—$16M
2319INMUNE BIO, INC.—$8.0M
2320ARUKA BIO, INC.—$3.6M
2321Genomics PLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 9 related persons
  • Brian AtwoodDirector · Executive Officer
  • Michael ByrnesDirector
  • Chris EhrlichDirector · Executive Officer
  • Andrew KucharchukExecutive Officer
  • Kathleen LaPorteDirector
  • Shami PatelDirector
  • Kristen PierceExecutive Officer
  • Robyn RapaportDirector
  • Lindsey RolfeDirector

Patents

USPTO · 2 granted of 10
  • Chimeric Tim Receptors And Uses Thereofapplication
  • Chimeric Tim Receptors And Uses Thereofgranted
  • Cellular Immunotherapy Compositions And Uses Thereofapplication
  • Chimeric TIM4 Receptors And Uses Thereofapplication
  • Compositions And Methods For Treating Cancer With Chimeric Tim Receptors In Combination With Inhibitors Of Poly (adp-ribose) Polymeraseapplication
  • Chimeric TIM4 Receptors And Uses Thereofgranted
  • Chimeric TIM4 Receptors And Uses Thereofapplication
  • ANTI-CD72 Chimeric Receptors And Uses Thereofapplication
  • Chimeric Tim Receptors And Uses Thereofapplication
  • Chimeric Engulfment Receptor Molecules And Methods Of Useapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.